Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Juli 2019 07:00 ET | Quelle: Akcea Therapeutics, Inc.

Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast

BOSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 6th...
16. Juli 2019 07:00 ET | Quelle: Akcea Therapeutics, Inc.; Ambry Genetics Corporation

hATTR Compass™ Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch

BOSTON and Aliso Viejo, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation (“Ambry”), a...
26. Juni 2019 07:00 ET | Quelle: Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.

Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress

BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
20. Juni 2019 16:38 ET | Quelle: Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.

Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting

BOSTON and CARLSBAD, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
28. Mai 2019 07:00 ET | Quelle: Akcea Therapeutics, Inc.

Akcea Therapeutics to Present at Upcoming Investor Conferences

BOSTON, May 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...
08. Mai 2019 16:05 ET | Quelle: Akcea Therapeutics, Inc.

Akcea Reports Financial Results and Highlights for First Quarter 2019

Achieved First Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $7 Million Novartis exercised its option to license AKCEA-APO(a)-LRx Received marketing authorization for WAYLIVRA®...
07. Mai 2019 16:05 ET | Quelle: Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.

New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

NEURO-TTR phase 3 open-label extension study showed TEGSEDI® (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy ...
07. Mai 2019 08:41 ET | Quelle: Akcea Therapeutics, Inc.

Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union

BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS),...
02. Mai 2019 07:05 ET | Quelle: Akcea Therapeutics, Inc.

Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)

Multiple clinical presentations at AAN focus on the long-term clinical benefits of treatment with TEGSEDI™ (inotersen) An oral presentation of long-term efficacy and safety with 2-year data from...
24. April 2019 07:00 ET | Quelle: Akcea Therapeutics, Inc.

Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast

BOSTON, April 24, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Wednesday, May 8th...

Vorherige Seite